


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. McLaren Oakland</p>	<p>In accordance with letter dated March 21, 2024.</p>	<p>4. Expiration Date: August 31, 2039</p>
<p>2. 50 N Perry St. Pontiac, MI 48342</p>	<p>3. License No.: 21-04081-03 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02041 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-04081-03

Docket or Reference No.:
030-02041

Amendment No. 65

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Best Medical International, Inc., Model 2301; Medi-Physics, Inc. d/b/a GE Healthcare, Model 6733 (EchoSeed) and 6711 (OncoSeed); Theragenics Corporation, Model I-Seed I25.S06 and I-Seed AgX100)	D. 600 millicuries total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation, Model TheraSeed 200)	E. 600 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Yttrium-90 permitted by 10 CFR 35.1000	F. Microspheres (Sirtex Wilmington LLC, Model Sirtex Medical SIR-Spheres microspheres)	F. 189 millicuries per vial and 2 curies total	F. For use in permanent manual brachytherapy using Sirtex Wilmington LLC Model SIR-Spheres Yttrium-90 microspheres and delivery system permitted by 10 CFR 35.1000.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-04081-03

Docket or Reference No.:
030-02041

Amendment No. 65

CONDITIONS

10. A. Licensed material shall be used or stored at the licensee's facilities located at 50 N Perry St., Pontiac, Michigan, 48342.
B. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used or stored at the licensee's facilities located at McLaren Diagnostic Imaging, 5701 Bow Pointe Dr., Clarkson, Michigan, 48346.
11. The Radiation Safety Officer (RSO) for this license is Adam R. Schwaderer, D.O.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Kevin R. Carter, D.O.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Stephen D. Franklin, M.D.

10 CFR 35.400

Arthur J. Frazier, M.D.

10 CFR 35.300,10 CFR 35.400

Mohamed Jaber, M.D.

10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Adam R. Schwaderer, D.O.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Kenneth P. Tarr, D.O.

10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-04081-03

Docket or Reference No.:
030-02041

Amendment No. 65

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Letter dated March 21, 2024 (ML24088A250)
- B. Letter dated May 24, 2024 (ML24145A148)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 29, 2024

By: **FRANK TRAN** Digitally signed by FRANK TRAN
Date: 2024.08.29 14:24:29 -05'00'

Frank P. D. Tran
Region 3